期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 20, 期 2, 页码 161-178出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2021.1941868
关键词
Combination therapy; caspofungin; candida species; antifungal effect; potential antifungal agents
资金
- Beijing Health Alliance Charitable Foundation [WS630A]
The review highlights the importance of combination therapy with caspofungin in treating refractory Candida infections and the need for further research on its efficacy. Additionally, novel compounds with potential antifungal activities show synergistic interactions with caspofungin, indicating promising directions for future studies on combating Candida species.
Introduction: Candida species have been regarded as global health threats due to their ability to cause invasive infections. It is challenging to treat Candida bloodstream infections, which are associated with high mortality levels. Monotherapy with antifungals is sometimes not effective against severe Candida infections, and combination therapy is needed in clinical practice. Areas covered: This review was undertaken based on data from a PubMed search for English language reports published before March 2021 by using the terms 'caspofungin,' 'Candida species,' 'combination therapy,' 'antifungal effect,' and 'novel antifungal agent.' Expert opinion: Combination therapy is an empirical strategy for treating refractory Candida infections. Caspofungin has been recommended to treat candidaemia. Caspofungin in combination therapy has some applications, while the efficacy of combination therapy in the treatment of refractory Candida infections needs more study, such as randomized controlled trials. In addition, novel compounds or drugs with potential antifungal activities have been examined, and some of them exhibit synergistic interactions with caspofungin. Thus, the antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy is summarized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据